Xanthus Life Sciences Changes Name to Xanthus Pharmaceuticals
News Feb 23, 2006
Xanthus Life Sciences, Inc. has announced that it has changed its corporate name to Xanthus Pharmaceuticals, Inc. The name change aligns the Company's corporate name with its strategic focus to build a differentiated specialty pharmaceuticals business.
"The last two years' efforts have focused on the development of the Company's clinical pipeline, which today includes two exciting compounds in clinical development and a third expected to enter the clinic later this year," stated Richard T. Dean, Ph.D., President and CEO of Xanthus.
"2006 will be an important building year for the Company as we develop our rapidly evolving pipeline and seek to in-license additional compounds to complement our portfolio."
"As such, we felt a change in our corporate name to Xanthus Pharmaceuticals, Inc. more appropriately describes our strategic focus."
Old age is the greatest risk factor for many diseases, including Alzheimer's disease (AD) and cancer. Geroprotectors are a recently identified class of anti-aging compounds. New research has now identified a unique subclass of these compounds, dubbed geroneuroprotectors (GNPs), which are AD drug candidates and slow the aging process in mice.READ MORE